Morin, a novel liver X receptor α/β dual antagonist, has potent therapeutic efficacy for nonalcoholic fatty liver diseases.
Ming GuYu ZhangChuhe LiuDongshan WangLi FengShengjie FanBaican YangQingchun TongGuang JiShengjie FanPublished in: British journal of pharmacology (2017)
Our data reveal that morin is a dual antagonist of LXRα and LXRβ and suggest that morin may alleviate hepatic steatosis and other associated metabolic disorders via the suppression of LXR signalling and, therefore, shows promise as a novel therapy or nutraceutical for nonalcoholic fatty liver disease.